Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx

Stanford University

Status: Completed

Conditions: Pancreatic Cancer

Treatments: Drug: FDG; Drug: FLT; Procedure: PET Scan

Study type: Interventional

Funder types: Other

Identifiers

NCT00767273

SU-11052007-795 (Other Identifier)

PANC0004

95733

Details and patient eligibility

About

To test the ability of new imaging techniques to monitor and predict response of pancreatic cancer to radiation and/or chemotherapy.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:- Adult patients (>18) with histologically confirmed adenocarcinomas of the pancreas with a - treatment plan consisting of definitive or palliative radiation therapy and/or chemotherapy with or without surgery.

• Negative urine pregnancy test if a woman of child-bearing potential (WOCBP).

• WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study period.

• All patients will be evaluated in a uniform manner at the Stanford GI Combined Modality Tumor Board to determine eligibility. Exclusion Criteria:1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

  2. Any concurrent malignancy other than non-melanomaskin cancer, or carcinomainsitu of the cervix. Patients with a previous malignancy without evidence of disease for >5 years will be allowed to enter the trial.

  3. WOCBP who is pregnant or breastfeeding. 4. Inability to sign written consent.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)